Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02886065
Title A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Massachusetts General Hospital

smoldering myeloma



Durvalumab + PVX-410

Durvalumab + Lenalidomide + PVX-410

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Massachusetts general Hospital Recruiting Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Medical Center Recruiting Boston Massachusetts 02115 United States Details
Dana-Farber Cancer Institute Recruiting Boston Massachusetts 02215 United States Details
Duke University Medical Center Recruiting Durham North Carolina 27710 United States Details
University Hospital of Cleveland- Seidman Cancer Center Recruiting Cleveland Ohio 44106 United States Details
*Shaded cells indicate that there was no data available from for the field